EXEL short interest
Exelixis Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 28,183,726 |
|---|---|
| Change vs prior report | 1,783,270 (+6.8%) |
| Change over six months | +3.4% |
| Days to cover | 12.65 (sector: 3.78) |
| Average daily volume | 2,228,196 |
| Rank in Healthcare | #62 of 922 by days to cover |
EXEL short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 28,183,726 | +6.8% | 12.65 | 2,228,196 |
| 2026-09-15 | 26,400,456 | -7.9% | 12.38 | 2,131,655 |
| 2026-08-31 | 28,656,285 | +2.2% | 14.88 | 1,925,986 |
| 2026-08-14 | 28,031,459 | -2.5% | 8.71 | 3,217,483 |
| 2026-07-31 | 28,749,664 | -7.0% | 13.42 | 2,142,046 |
| 2026-07-15 | 30,913,414 | +8.3% | 12.67 | 2,439,206 |
| 2026-06-30 | 28,539,118 | -6.8% | 8.58 | 3,327,761 |
| 2026-06-15 | 30,635,016 | +3.1% | 13.54 | 2,261,904 |
| 2026-05-29 | 29,707,071 | -1.9% | 12.35 | 2,404,618 |
| 2026-05-15 | 30,278,606 | +0.9% | 9.17 | 3,303,551 |
| 2026-04-30 | 30,010,146 | +6.0% | 12.64 | 2,374,709 |
| 2026-04-15 | 28,306,926 | +3.8% | 13.09 | 2,163,233 |
| 2026-03-31 | 27,263,165 | +3.5% | 11.00 | 2,478,249 |
| 2026-03-13 | 26,352,704 | +0.1% | 7.37 | 3,575,723 |
| 2026-02-27 | 26,323,621 | -8.6% | 9.90 | 2,658,986 |
| 2026-02-13 | 28,805,341 | +3.3% | 10.12 | 2,847,372 |
| 2026-01-30 | 27,879,825 | +8.2% | 11.84 | 2,354,811 |
| 2026-01-15 | 25,766,783 | +4.3% | 10.03 | 2,569,651 |
| 2025-12-31 | 24,704,144 | +8.2% | 10.65 | 2,318,670 |
| 2025-12-15 | 22,834,554 | +6.9% | 8.54 | 2,672,661 |
| 2025-11-28 | 21,360,218 | +6.0% | 8.62 | 2,477,165 |
| 2025-11-14 | 20,145,618 | +1.8% | 6.41 | 3,141,897 |
| 2025-10-31 | 19,791,732 | -5.2% | 6.20 | 3,192,239 |
| 2025-10-15 | 20,882,902 | +17.7% | 9.07 | 2,302,357 |
| 2025-09-30 | 17,746,951 | +0.9% | 6.90 | 2,573,204 |
import finzdata as yf
yf.Ticker("EXEL").short_interest # every report since 2017
yf.Client().short_interest(["EXEL"], start="2018-01-01")Healthcare short interest · EXEL price history · Who owns EXEL · All short interest